[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"somatosensory-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:somatosensory-function":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":42,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100600783","hyperthermia-in-patients-with-chronic-primary-pain---effects-on-thermoregulation-somatosensory-system-and-movement-evoked-pain-100600783",false,"NCT07101978","Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain","Hyperthermia in Healthy and Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System, Movement Evoked Pain (HYPPRI-1)","HYPPRI-1","Inclusion Criteria:\n\npatients:\n\n* Confirmed diagnosis of widespread pain (ICD-11 MG30.01)\n* Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) scale ≥ 5 or WPI) ≥ 3 and SS ≥ 9,\n* Pain \\>= 3 month and VAS \\>= 4,0\n* Body - infrared-A-Bulb Distance \\\u003C 38cm (overweight participants)\n* Signed declaration of consent\n\nhealthy:\n\n* No chronic illnesses\n* No acute infections\n* No regular medication: To avoid interactions\n* BMI ≤ 40kg\u002Fcm2\n* Mental health: No psychiatric diagnoses or psychotropic medication in your medical history\n\nExclusion Criteria:\n\n* Participation in other clinical studies\n* Contraindications for hyperthermia (severe cardiovascular diseases, tumour diseases, acute infections, pregnant and breastfeeding women)\n* Acute and \u002F or feverish microbial infections\n* Participants with severe somatic, rheumatic concomitant endocrine or neurological diseases, in particular neurological diseases associated with cognitive disorders, severe liver or kidney and cardiac diseases\n* participants who are permanently treated with opioids, cannabis, immunosuppressive drugs (e.g. corticoids, immunosuppressants) or alpha\u002Fbeta-A(nta)gonists due to a disease from the group described above\n* participants with pain due to a serious psychiatric illness (bipolar disorder, psychosis, personality disorder, severe depression, substance abuse) and serious systemic or neurological disorders\n* pregnancy or breastfeeding (for women)\n* Intake of medication within 6 weeks that inhibits the reuptake of the neurotransmitter serotonin or binds to receptors of this neurotransmitter group",true,"ALL","18 Years","70 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study, in a quasi-experimental matched two-group pre-post design, investigates the effect of serial water-filtered whole-body hyperthermia on circadian core body temperature, the somatosensory system (nociception) and the movement evoked pain in healthy and patients with chronic primary pain (e.g., fibromyalgia). The intervention lasts 3 weeks with two treatment sessions per week.",[29,30,31,32,33,34,35,36,37,38,39,40,41],"Hyperthermia","Chronic Primary Pain","Widespread Pain","Muscular Disease","Rheumatic Diseases","Musculoskeletal Diseases","Neuromuscular Disease","Fibromyalgia","Circadian Rhythm","Body Temperature Changes","Somatosensory Function","Quantitative Sensory Testing","Healthy",[43,44,45,46,47,48],"hyperthermia","widespread pain","chronic primary pain","circadian body temperature","quantitative sensory testing","healthy","NOT_YET_RECRUITING","2026-05-29",{"date":52,"type":53},"2026-06-02","ACTUAL",{"date":55,"type":23},"2026-08-01",{"date":57,"type":23},"2028-12-31",{"name":59,"class":60},"Bern University of Applied Sciences","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":18,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":24,"phases":73,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":61},"100575380","brain-stimulation-for-foot-sole-sensation-in-older-adults-with-foot-sole-somatosensory-deficits-100575380","NCT06771531","Brain Stimulation for Foot-sole Sensation in Older Adults With Foot-sole Somatosensory Deficits","Cortical Mechanisms and Modulation of Somatosensation in Older Adults With Foot Sole Somatosensory Impairments","BSFS","Inclusion Criteria:\n\n1. Aged ≥65 years.\n2. Self-reported feeling of unsteadiness or difficulty when standing and walking.\n3. Mild-to-moderate foot-sole somatosensory impairment: the ability to perceive 75g monofilament but inability to perceive 10g monofilament.\n\nExclusion Criteria:\n\n1. self-reported inability to stand or walk continuously for one minute without personal assistance (canes or walkers allowed);\n2. history or presence of foot ulceration, amputation, or deformities;\n3. self-reported uncontrolled pain or pain that is associated with mobility disability;\n4. uncontrolled diabetes mellitus;\n5. hospitalization within the past three months due to acute illness, or as the result of a musculoskeletal injury significantly affecting balance;\n6. persistent severe pain of lower extremity when standing or walking;\n7. diagnosis of dementia, Parkinson's disease, or stroke that affects balance;\n8. unstable medical condition;\n9. legal blindness or deafness;\n10. uncontrolled hypertension (i.e., systolic BP \\>180, diastolic BP \\>100 mm Hg, or prescription of ≥3 anti-hypertensive medications);\n11. functionally limiting nephropathy, severe diseases or transplant of the kidney or liver, renal or congestive heart failure;\n12. active cancer treatment;\n13. balance disorders due to past use of chemotherapy or history of Guillain-Barré syndrome;\n14. use of neuro-active or recreational drugs (e.g., sedatives, anti-psychotics), or alcohol abuse, which may affect the brain excitability;\n15. contraindications to MRI or tDCS (e.g., personal or family history of seizures or epilepsy, metallic or electric bio-implants, claustrophobia, brain surgery);\n16. persistent vertigo;\n17. history of Charcot-Marie-Tooth nerve disease.","65 Years",{"count":72,"type":23},20,[26],"In older adults, diminished sensation of the legs and feet is highly prevalent and causes poor balance and reduced mobility. This type of sensation is not only dependent upon the receptors and nerves in the legs and feet, but also upon a complex central nervous system pathway that includes the cerebral cortex of the brain. This project will use a form of noninvasive brain stimulation called transcranial direct current stimulation (tDCS) to test whether increasing the excitability of the brain networks that process sensory feedback can augment foot sole sensation, balance, and mobility in older adults suffering from mild-to-moderate foot sole sensory impairments.",[39,76,77],"Balance Control","Mobility",[79,80,81],"brain stimulation","balance and mobility","foot-sole somatosensory function","RECRUITING","2026-04-21",{"date":85,"type":53},"2026-04-22",{"date":87,"type":53},"2026-02-26",{"date":89,"type":23},"2026-12-31",{"name":91,"class":60},"Hebrew SeniorLife"]